Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Long-term relapse prevention with risperidone in 215 schizophrenic patients].

C Udina Abelló1, M Roca Bennasar, I Octavio Del Valle

  • 1Hospital General de Cataluña. Universidad Autónoma de Barcelona, Spain.

Actas Espanolas De Psiquiatria
|July 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Frontal lobe involvement and cortical and subcortical deterioration in Parkinson's disease evaluated using quantified electroencephalography].

Archivos de neurobiologia·1991
Same author

[Attitudes toward epilepsy in Majorca].

Archivos de neurobiologia·1989
Same author

Plasma and red cell lithium.

The British journal of psychiatry : the journal of mental science·1980
Same author

[Interdepartmental psychiatric consultation in a general hospital].

Actas luso-espanolas de neurologia, psiquiatria y ciencias afines·1980

This 18-month study found risperidone effective in preventing schizophrenia relapses for over 80% of patients. The medication showed good safety, with most patients tolerating it well and experiencing symptom improvement.

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • An 18-month open-label, postmarketing surveillance study evaluated risperidone in 215 patients with schizophrenia (DSM-IV criteria).
  • The study focused on assessing the safety and effectiveness of risperidone in preventing relapse.

Purpose of the Study:

  • To evaluate the safety and effectiveness of risperidone in preventing relapse in adult patients with schizophrenia.
  • To assess the impact of risperidone on psychotic symptoms, global functioning, and neurological side effects.

Main Methods:

  • Utilized the Brief Psychiatric Rating Scale, Global Functional Assessment Scale, and Clinical Global Impression for efficacy assessment.
  • Employed the UKU subscale for neurological side effects to evaluate safety.
  • Included 215 patients diagnosed with schizophrenia according to DSM-IV criteria.

Related Experiment Videos

Main Results:

  • 82.1% of patients remained relapse-free during the 18-month study period.
  • Mean daily dosage of risperidone was 5.69 ± 2.41 mg.
  • Significant reductions in neurological side effects were observed (mean total UKU subscale score).

Conclusions:

  • Risperidone improved psychotic symptoms and global activity in patients with schizophrenia.
  • The drug demonstrated a favorable safety profile, with 91.7% of patients reporting no adverse events.
  • Only 1.2% of patients discontinued treatment due to intolerance, indicating good tolerability.